Orchid Pharma Limited

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about General Updates, specifically that the Board of Directors has approved a proposal to explore the potential market opportunities for raising funds by issuing equity shares or other eligible securities, up to Rs. 600 Crores.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 20, 2026, where the Board of Directors considered and approved a proposal to explore the potential market opportunities for raising funds by way of issue of equity shares or other eligible securities, up to Rs. 600 Crores.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the compliances required under the regulation for the Quarter- II of Financial Year 2026-27.

Orchid Pharma Limited

Orchid Pharma Limited has submitted the Exchange a copy Scrutinizer's report of 33rd Annual General Meeting held on September 29, 2026, and informed the Exchange regarding voting results.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding Proceedings of the 33rd Annual General Meeting held on September 29, 2026. The meeting was held through Video Conferencing and was attended by 32 members. The Chairman, Mr. Manish Dhanuka, confirmed the presence of requisite quorum and called the meeting to order. The Notice of AGM dated September 07, 2026 was taken as read and the Chairman delivered his speech highlighting Company's journey throughout the Financial Year 2025-26 with some financial insights.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding 'Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation'. The company has listed and admitted 4,45,86,052 equity shares to dealings on NSE and BSE with effect from September 23, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about the purchase of a land situated at Patibulum Village, Kancheepuram District, Tamil Nadu, marking the permanent closure of the Company's arrangement with DBS Bank India Limited.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding 'Investor Roadshow Scheduled to be held in Mumbai'. The company will participate in the Investor Roadshow on September 28-30, 2026, in Mumbai. No unpublished price sensitive information will be shared during the meet.

Orchid Pharma Limited

Orchid Pharma Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26, as per the provisions of Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about the appointment of a cost auditor and change in designation of a Director, Mr. Arjun Dhanuka, to Whole-Time Director.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026, where the Board of Directors approved the appointment of Cost Auditors for FY 2026-27, appointment of Mr. Arjun Dhanuka as Whole-Time Director, and other matters.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about the transcript of Analysts/ Investors Earning Call held with Public at large on August 21, 2026, on the financial performance/ financial results of the Company for the Quarter-I of Financial Year 2026-27, ended on June 30, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has uploaded the audio recording of its analysts/investors earnings call on its website, discussing unaudited Q1 FY 2026-27 financial results.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about Presentation for Investors, including financial performance for the Quarter-I of Financial Year 2026-27, ended on June 30, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange about the schedule of an Analysts/Investors Earning Call hosted by 'Systematix Institutional Equities' to discuss the financial results/ performance of the Company for the Quarter-I ended on June 30, 2026.

Orchid Pharma Limited

Orchid Pharma Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, in relation to the Qualified Institutional Placement (QIP) of Rs. 400 crores. The report states that there are no deviations from the objects of the issue and the utilization of the issue proceeds is as per the disclosures in the statements.

Orchid Pharma Limited

Orchid Pharma Limited has submitted its revised audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, following the sanctioned scheme of amalgamation and arrangement of Dhanuka Laboratories Limited with Orchid Pharma Limited.

Orchid Pharma Limited

Orchid Pharma Limited has submitted its financial results for the period ended June 30, 2026, to the NSE.